Biohaven Pharmaceutical Holding Company Ltd. (BHVN) financial statements (2020 and earlier)

Company profile

Business Address 215 CHURCH STREET
NEW HAVEN, CT 06510
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments317264131
Cash and cash equivalents317264131
Prepaid expense475
Other current assets000
Other undisclosed current assets800
Total current assets:328272137
Noncurrent Assets
Property, plant and equipment862
Long-term investments and receivables5118
Long-term investments5118
Other undisclosed noncurrent assets200
Total noncurrent assets:161810
TOTAL ASSETS:344290147
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities66209
Accounts payable14115
Accrued liabilities5295
Total current liabilities:66209
Noncurrent Liabilities
Liabilities, other than long-term debt14121
Financial instruments subject to mandatory redemption, settlement terms, share value, amount104  
Other liabilities021
Derivative instruments and hedges, liabilities38  
Other undisclosed noncurrent liabilities1441184
Total noncurrent liabilities:2861205
Total liabilities:35213915
Stockholders' equity
Stockholders' equity attributable to parent(7)151132
Common stock881554311
Additional paid in capital844024
Accumulated deficit(972)(444)(203)
Total stockholders' equity:(7)151132
TOTAL LIABILITIES AND EQUITY:344290147

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Operating expenses(479)(225)(108)
Operating loss:(479)(225)(108)
Nonoperating expense(49)(16)(19)
Other nonoperating expense(0)(0)(19)
Interest and debt expense(13)(0)(1)
Other undisclosed income from continuing operations before equity method investments, income taxes1301
Loss from continuing operations before income taxes:(528)(240)(126)
Income tax expense(0)(0)(1)
Net loss attributable to parent:(529)(241)(127)
Other undisclosed net loss available to common stockholders, basic  (12)
Net loss available to common stockholders, diluted:(529)(241)(139)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net loss:(529)(241)(127)
Comprehensive loss, net of tax, attributable to parent:(529)(241)(127)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: